Last reviewed · How we verify
Dabigatran Etexilate 150mg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Dabigatran Etexilate 150mg (Dabigatran Etexilate 150mg) — Kafrelsheikh University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dabigatran Etexilate 150mg TARGET | Dabigatran Etexilate 150mg | Kafrelsheikh University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dabigatran Etexilate 150mg CI watch — RSS
- Dabigatran Etexilate 150mg CI watch — Atom
- Dabigatran Etexilate 150mg CI watch — JSON
- Dabigatran Etexilate 150mg alone — RSS
Cite this brief
Drug Landscape (2026). Dabigatran Etexilate 150mg — Competitive Intelligence Brief. https://druglandscape.com/ci/dabigatran-etexilate-150mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab